Hengrui Medicine Plans to Sell Shares to Fund Purchase of 51% Stake in Local Coal Miner - Marketscreener.com

1 year ago 40

Homepage Equities China Shanghai Stock Exchange Jiangsu Hengrui Medicine Co., Ltd. News Summary     600276   CNE0000014W7 (600276) Add to my list   Report End-of-day punctuation Shanghai Stock Exchange  -  2022-12-11 38.88 CNY   +0.15% 12/12 Hengrui Medicine Plans to Sell Shares to Fund Purchase of 51% Stake successful Local Coal Miner MT 12/11 Fire Rock CFO Resigns MT 11/22 US FDA Approves Jiangsu Hengrui's MRI Contrast Agent MT Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds   Summary Most relevant All News Analyst Reco. Other languages Press Releases Official Publications Sector news 12/12/2022 | 09:49pm EST MT Newswires 2022 Stocks mentioned successful the article Change Last 1st jan. HUADIAN POWER INTERNATIONAL CORPORATION LIMITED  1.80% 2.83 -18.24% JIANGSU HENGRUI MEDICINE CO., LTD.  0.15% 38.88 -23.33% UNITED STATES DOLLAR (B) / CHINESE YUAN IN HONG KONG (USD/CNH)  -0.06% 6.9819 9.57% All quality about JIANGSU HENGRUI MEDICINE CO., LTD. 12/12 Hengrui Medicine Plans to Sell Shares to Fund Purchase of 51% Stake successful Local Coal Miner MT 12/11 Fire Rock CFO Resigns MT 11/22 US FDA Approves Jiangsu Hengrui's MRI Contrast Agent MT 11/18 Hengrui Pharmaceuticals' Anti-Cancer Drug Combination Put successful Regulator's Priority Revie.. MT 11/17 Hengrui Pharmaceuticals Unit Gets Clinical Trial Approval for Malignant Tumor Treatment.. MT 11/07 COP27: Major nutrient firms item plans to destruct deforestation by 2025 RE 10/31 Jiangsu Hengrui Medicine's Q3 Profit Slumps 32% arsenic Revenue Slides 17% MT 10/28 Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended S.. CI 10/24 Hengrui Pharmaceuticals' Lung Cancer Treatment Gets Breakthrough Therapy Designation in.. MT 10/11 Tranche Update connected Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on.. CI More news Analyst Recommendations on JIANGSU HENGRUI MEDICINE CO., LTD. 08/22 Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 34.13 Yuan From 31.71 Y.. MT 04/25 Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 31.71 Yuan From 55.66 Y.. MT More recommendations Financials Sales 2022 22 382 M 3 208 M 3 208 M Net income 2022 4 339 M 622 M 622 M Net currency 2022 19 772 M 2 834 M 2 834 M P/E ratio 2022 57,1x Yield 2022 0,34% Capitalization 248 B 35 537 M 35 537 M EV / Sales 2022 10,2x EV / Sales 2023 8,80x Nbr of Employees 24 491 Free-Float 48,4% More Financials Chart JIANGSU HENGRUI MEDICINE CO., LTD. Duration : Period : Full-screen chart Technical investigation trends JIANGSU HENGRUI MEDICINE CO., LTD. Short Term Mid-Term Long Term Trends Bearish Bullish Neutral Technical analysis Income Statement Evolution More Financials Consensus Sell Buy Mean consensus BUY Number of Analysts 21 Last Close Price 38,88 CNY Average people price 52,51 CNY Spread / Average Target 35,1% Consensus EPS Revisions More Estimates Revisions Managers and Directors Wei Dong Chairman-Supervisory Board Piao Yang Sun Chairman Xiao-Jing Zhang Chief Medical Officer Yu Xu Compliance Manager Shuang Xue Independent Director More astir the company Sector and Competitors 1st jan. Capi. (M$) JIANGSU HENGRUI MEDICINE CO., LTD. -23.33% 35 537 JOHNSON & JOHNSON 2.73% 459 469 ELI LILLY AND COMPANY 30.69% 343 005 NOVO NORDISK A/S 25.40% 295 189 PFIZER, INC. -12.41% 290 321 ABBVIE INC. 20.43% 288 271 More Results

1. Homepage
2. Health
3. Hengrui Medicine Plans to Sell Shares to Fund Purchase of 51% Stake in Local Coal Miner - Marketscreener.com